Editing CAR T cells to produce inflammatory cytokines helps them enter solid tumors and promote cancer killing.
Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...
CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...
A panelist discusses how CD4 counts serve as measures of immune system status that typically increase by about 200 in the first year of antiretroviral therapy. Although there can be laboratory ...
Like the surface of the moon, new research published today in Cell finds the existence of craters on the surface of melanoma cells that serve as immune hubs, becoming major sites for tumor killing.
Immune-inflammatory skin diseases (e.g., psoriasis, atopic dermatitis) involve dysregulation of CD4+ T-cell subsets (Th1/Th2/Th17/Treg) and cytokine networks (IL-17/IL-23/IL-4). Biologics targeting ...
Measuring the lymphocytes - white blood cells that fight infection - in a patient's blood can be used to predict outcomes in non-Hodgkin lymphoma patients who receive CAR T-cell therapy, according to ...
A study has traced immune activity at high resolution in the first living recipient of a gene-edited pig kidney and has reported that – even after clinicians suppressed T-cell rejection – ...
Researchers highlight how exercise and dietary strategies may complement immunotherapy by improving immune function, tumour perfusion, and quality of life.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results